136 related articles for article (PubMed ID: 3166086)
1. 6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.
Hayder S; Lafolie P; Björk O; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1988; 5(3):187-9. PubMed ID: 3166086
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia.
Jacqz-Aigrain E; Nafa S; Médard Y; Bessa E; Lescoeur B; Vilmer E
Eur J Clin Pharmacol; 1997; 53(1):71-4. PubMed ID: 9349933
[TBL] [Abstract][Full Text] [Related]
3. Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.
Lafolie P; Björk O; Hayder S; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1989; 6(4):259-65. PubMed ID: 2615529
[TBL] [Abstract][Full Text] [Related]
4. Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid.
Covell DG; Narang PK; Poplack DG
Am J Physiol; 1985 Feb; 248(2 Pt 2):R147-56. PubMed ID: 4038588
[TBL] [Abstract][Full Text] [Related]
5. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
[TBL] [Abstract][Full Text] [Related]
6. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Lennard L; Keen D; Lilleyman JS
Clin Pharmacol Ther; 1986 Sep; 40(3):287-92. PubMed ID: 3461899
[TBL] [Abstract][Full Text] [Related]
7. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
Lafolie P; Hayder S; Björk O; Peterson C
Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
[TBL] [Abstract][Full Text] [Related]
8. Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse.
Morse M; Savitch J; Balis F; Miser J; Feusner J; Reaman G; Poplack D; Bleyer A
J Clin Oncol; 1985 Jan; 3(1):19-24. PubMed ID: 3855310
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
[TBL] [Abstract][Full Text] [Related]
11. 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity.
Hayder S; Lafolie P; Björk O; Peterson C
Ther Drug Monit; 1989 Nov; 11(6):617-22. PubMed ID: 2595740
[TBL] [Abstract][Full Text] [Related]
12. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
13. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma.
Lafolie P; Hayder S; Björk O; Ahström L; Liliemark J; Peterson C
Acta Paediatr Scand; 1986 Sep; 75(5):797-803. PubMed ID: 3564948
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study.
Adamson PC; Balis FM; Arndt CA; Holcenberg JS; Narang PK; Murphy RF; Gillespie AJ; Poplack DG
Cancer Res; 1991 Nov; 51(22):6079-83. PubMed ID: 1933871
[TBL] [Abstract][Full Text] [Related]
15. Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia.
Riccardi R; Lasorella A; Tartaglia RL; Riccardi A; Servidei T; Mastrangelo R
Med Oncol Tumor Pharmacother; 1991; 8(2):95-8. PubMed ID: 1749306
[TBL] [Abstract][Full Text] [Related]
16. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
[TBL] [Abstract][Full Text] [Related]
17. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
[TBL] [Abstract][Full Text] [Related]
18. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
Hayder S; Björk O; Lafolie P
Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
Lowe ES; Kitchen BJ; Erdmann G; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Woods W; Franklin J; Widemann BC; Balis FM; Murphy RF; Adamson PC
Cancer Chemother Pharmacol; 2001 Mar; 47(3):199-205. PubMed ID: 11320662
[TBL] [Abstract][Full Text] [Related]
20. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
